Is loss of CD10 ( neutral endopeptidase ) a frequent and early event in human prostate cancer?
These findings demonstrate that loss or decreased expression of CD10 is an early and frequent event in human prostate cancer and implicates CD10 as a potential therapeutic target for early stage hormone sensitive prostate cancer.
Providing patients with personalized video recordings of their clinical visits has not resulted in increased legal risk to providers. In addition, the use of the recording by patients to answer their own questions without needing to call the office can result in significant savings to practice costs.